Andrea Jayne Frederick, NP
Family · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Andrea Jayne Frederick’s office at (650) 724-9220 to ask if they take your plan before you enroll.
California Medical Board record
Licence C19137 · Cancelled
Licence status: Cancelled · since 1957 · Loyola University of Chicago Stritch School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 11 Part D prescriptions in 2020. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2020 | 11 | None | 0% (0) | None | $1,234 |
| 2014 | 23 | None | 0% (0) | 52% | $100 |
| 2013 | 84 | 11 | None | 19% | $1,800 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2014: 1 drug
| Furosemide | 12 | $23 | $2 |
2013: 2 drugs
| Spironolactone | 21 | $258 | $12 |
| Furosemide | 12 | $38 | $3 |
Money from drug and device companies
$17,026 in 2025
| 2025 | 2 | 30 | $16,000 | $17,026 |
| 2024 | 3 | 32 | None | $978 |
| 2023 | 2 | 56 | $7,530 | $10,533 |
| 2022 | 2 | 56 | $16,290 | $20,625 |
| 2021 | 3 | 15 | None | $438 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Revance Therapeutics | Daxxify | $16,793 | 22 payments
|
| Abbvie | Botox | $232 | 8 payments
|
See all 30 published payments
| Revance Therapeutics | Travel · 2025-12-17 | Daxxify | $63 |
| Revance Therapeutics | Paid to speak or teach · 2025-12-17 | Daxxify | $2,000 |
| Revance Therapeutics | Meals · 2025-12-15 | Daxxify | $31 |
| Revance Therapeutics | Paid to speak or teach · 2025-12-15 | Daxxify | $2,000 |
| Revance Therapeutics | Travel · 2025-12-15 | Daxxify | $76 |
| Abbvie | Meals · 2025-12-03 | Botox | $4 |
| Abbvie | Meals · 2025-12-02 | Botox | $4 |
| Revance Therapeutics | Meals · 2025-12-01 | None | $14 |
| Revance Therapeutics | Paid to speak or teach · 2025-12-01 | Daxxify | $2,000 |
| Revance Therapeutics | Travel · 2025-12-01 | Daxxify | $94 |
| Revance Therapeutics | Meals · 2025-11-25 | Daxxify | $10 |
| Revance Therapeutics | Paid to speak or teach · 2025-11-25 | Daxxify | $2,000 |
| Revance Therapeutics | Travel · 2025-11-25 | Daxxify | $55 |
| Abbvie | Meals · 2025-10-14 | None | $24 |
| Abbvie | Meals · 2025-09-18 | Botox | $24 |
| Abbvie | Meals · 2025-08-06 | None | $18 |
| Abbvie | Meals · 2025-07-02 | None | $9 |
| Revance Therapeutics | Meals · 2025-05-22 | Daxxify | $36 |
| Revance Therapeutics | Paid to speak or teach · 2025-05-22 | Daxxify | $2,000 |
| Abbvie | Meals · 2025-05-09 | Botox | $30 |
| Abbvie | Meals · 2025-04-29 | Botox | $120 |
| Revance Therapeutics | Paid to speak or teach · 2025-03-18 | Daxxify | $2,000 |
| Revance Therapeutics | Travel · 2025-03-18 | Daxxify | $144 |
| Revance Therapeutics | Meals · 2025-03-03 | Daxi | $6 |
| Revance Therapeutics | Paid to speak or teach · 2025-03-03 | Daxxify | $2,000 |
| Revance Therapeutics | Travel · 2025-03-03 | Daxxify | $64 |
| Revance Therapeutics | Meals · 2025-03-02 | None | $18 |
| Revance Therapeutics | Meals · 2025-01-28 | Daxxify | $144 |
| Revance Therapeutics | Paid to speak or teach · 2025-01-27 | Daxxify | $2,000 |
| Revance Therapeutics | Travel · 2025-01-27 | Daxxify | $41 |
See earlier years (2024, 2023, 2022, 2021)
2024: $978
| Abbvie | Botox | $498 | 19 payments
|
| Revance Therapeutics | Daxxify | $449 | 12 payments
|
| Merz North America | Xeomin | $31 | 1 payment
|
2023: $10,533
| Abbvie | Botox | $10,467 | 53 payments
|
| Galderma Laboratories L.P. | None | $67 | 3 payments
|
2022: $20,625
| Allergan | Botox | $20,562 | 53 payments
|
| Galderma Laboratories L.P. | None | $63 | 3 payments
|
2021: $438
| Allergan | Botox | $378 | 12 payments
|
| Galderma Laboratories L.P. | None | $39 | 2 payments
|
| Merz North America | Xeomin | $20 | 1 payment
|
Professional record
- NPI
- 1669782645
- Licence
- CA 19137California C19137: Cancelled
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 234 Beresford Ave, Redwood City, CA, 94061
- NPI first listed
- 2010-10-08
- NPI last updated
- 2010-10-08
This is when the NPI record was last certified, not a medical board exam.